Morgan Stanley’s SpringWorks Therapeutics SWTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-1,247,783
| Closed | -$58.6M | – | 8363 |
|
|
2025
Q2 | $58.6M | Buy |
1,247,783
+352,208
| +39% | +$15.7M | ﹤0.01% | 1779 |
|
|
2025
Q1 | $39.5M | Sell |
895,575
-1,101,701
| -55% | -$50.7M | ﹤0.01% | 2029 |
|
|
2024
Q4 | $72.2M | Buy |
1,997,276
+558,641
| +39% | +$19.5M | 0.01% | 1505 |
|
|
2024
Q3 | $46.1M | Buy |
1,438,635
+1,112,516
| +341% | +$41.6M | ﹤0.01% | 1900 |
|
|
2024
Q2 | $12.3M | Sell |
326,119
-254,943
| -44% | -$10.7M | ﹤0.01% | 3153 |
|
|
2024
Q1 | $28.6M | Buy |
581,062
+10,398
| +2% | +$481K | ﹤0.01% | 2299 |
|
|
2023
Q4 | $20.8M | Buy |
570,664
+42,702
| +8% | +$1.11M | ﹤0.01% | 2647 |
|
|
2023
Q3 | $12.2M | Buy |
527,962
+187,088
| +55% | +$5.12M | ﹤0.01% | 2932 |
|
|
2023
Q2 | $8.94M | Buy |
340,874
+12,969
| +4% | +$341K | ﹤0.01% | 3272 |
|
|
2023
Q1 | $8.44M | Sell |
327,905
-41,781
| -11% | -$1.22M | ﹤0.01% | 3301 |
|
|
2022
Q4 | $9.62M | Sell |
369,686
-385,931
| -51% | -$9.51M | ﹤0.01% | 3134 |
|
|
2022
Q3 | $21.6M | Buy |
755,617
+257,965
| +52% | +$7.4M | ﹤0.01% | 2110 |
|
|
2022
Q2 | $12.3M | Buy |
497,652
+347,754
| +232% | +$12.7M | ﹤0.01% | 2853 |
|
|
2022
Q1 | $8.46M | Buy |
149,898
+61,623
| +70% | +$3.53M | ﹤0.01% | 3103 |
|
|
2021
Q4 | $5.47M | Sell |
88,275
-24,961
| -22% | -$1.65M | ﹤0.01% | 3629 |
|
|
2021
Q3 | $7.18M | Buy |
113,236
+32,035
| +39% | +$2.47M | ﹤0.01% | 3304 |
|
|
2021
Q2 | $6.69M | Sell |
81,201
-52,665
| -39% | -$4M | ﹤0.01% | 3462 |
|
|
2021
Q1 | $9.85M | Buy |
133,866
+60,696
| +83% | +$4.75M | ﹤0.01% | 2673 |
|
|
2020
Q4 | $5.31M | Buy |
73,170
+63,039
| +622% | +$4.06M | ﹤0.01% | 3194 |
|
|
2020
Q3 | $483K | Sell |
10,131
-6,733
| -40% | -$287K | ﹤0.01% | 4664 |
|
|
2020
Q2 | $708K | Buy |
16,864
+15,807
| +1,495% | +$562K | ﹤0.01% | 4408 |
|
|
2020
Q1 | $29K | Sell |
1,057
-14,420
| -93% | -$470K | ﹤0.01% | 5679 |
|
|
2019
Q4 | $595K | Buy |
15,477
+9,045
| +141% | +$212K | ﹤0.01% | 4832 |
|
|
2019
Q3 | $139K | Buy |
+6,432
| New | +$152K | ﹤0.01% | 5314 |
|
Other funds holding SWTX
Morgan Stanley's SWTX Position: Q3 2025 in Review
Morgan Stanley sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 1,247,783 shares — an estimated $58.6M sold.
Morgan Stanley first reported a position in SWTX in Q3 2019 and held it in 24 quarters. The position peaked at $72.2M in Q4 2024. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.
- Morgan Stanley reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
- Morgan Stanley sold 1,247,783 SpringWorks Therapeutics shares in Q3 2025, an estimated $58.6M.
- Morgan Stanley first reported a position in SpringWorks Therapeutics in Q3 2019 and held it in 24 quarters.
- Morgan Stanley's SpringWorks Therapeutics position peaked at $72.2M in Q4 2024.
- 3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.
Based on Morgan Stanley's 13F filing for Q3 2025, filed 14 Nov 2025.